Van Cleef Asset Management Inc Reduces Position in Johnson & Johnson (NYSE:JNJ)

Van Cleef Asset Management Inc cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 23,053 shares of the company’s stock after selling 234 shares during the period. Van Cleef Asset Management Inc’s holdings in Johnson & Johnson were worth $3,334,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of JNJ. IFS Advisors LLC boosted its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $32,000. RPg Family Wealth Advisory LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at $35,000. Activest Wealth Management acquired a new stake in shares of Johnson & Johnson in the 3rd quarter worth $40,000. Finally, Fiduciary Advisors Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter worth $43,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. Raymond James cut their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Finally, Bank of America decreased their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.9 %

NYSE JNJ opened at $165.23 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market cap of $397.81 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52. The firm has a 50 day simple moving average of $150.90 and a 200-day simple moving average of $156.04. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.29 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.